Cancer News: Ovarian

Olaparib approved for maintenance ovarian cancer treatment

Olaparib has been approved for maintenance ovarian cancer treatment by the FDA, for women in complete or partial response to platinum-based chemotherapy.

Genetic tests not always done when recommended

Fewer women with history of breast and ovarian cancer take a recommended genetic test. This may increase their risk for additional cancers in the future.

FDA approves another use of bevacizumab for treating ovarian cancer

The U.S. FDA has approved bevacizumab for the treatment of patients with platinum-sensitive recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer.

Niraparib improves outcomes in patients with ovarian cancer

The PARP inhibitor niraparib improves primary and secondary endpoints in platinum-sensitive recurrent ovarian cancer. Survival was significantly improved.

Chronic inactivity linked to increased risk for ovarian cancer

The lack of regular exercise throughout adulthood is associated with an increased risk of developing and dying from ovarian cancer, a new analysis reveals.

Chemotherapy and immunotherapy against ovarian cancer

Immunotherapy given directly after chemotherapy to ovarian cancer patients stimulated immune cells that can kill cancer cells, a new analysis reveals.

Olaparib increased overall survival in relapsed ovarian cancer

Olaparib (Lynparza) induced positive patient outcomes in relapsed ovarian cancer patients, especially of the BRCAm mutation.

Ovarian Cancer: extended survival with hormonal maintenance therapy

Treating patients of low-grade serous carcinoma (LGSC) of the ovary or peritoneum with hormonal maintenance therapy improved progression-free survival.

Possible decreased fertility risk for ovarian cancer patients

An innovative study showed that there is a risk of a possible decreased fertility in ovarian cancer patients treated with radioactive iodine treatment.

Olaparib gets UK’s approval for ovarian cancer

UK’s regulators have recommended olaparib for adult patients with relapsed platinum-sensitive ovarian, fallopian tube and peritoneal cancer.

Screening may reduce mortality in ovarian cancer

According to the largest randomized trials in ovarian cancer, screening may reduce ovarian cancer mortality, as it can detect the disease sufficiently early.

Anxious about getting a genetic cancer screening?

Counseling before and after a genetic cancer screening helped BRCA 1/2-negative patients make informed decisions and deal with anxiety, a new research reveals.

Birth control pills tied to increased survival in ovarian cancer

Ovarian cancer patients who had previously taken birth control pills had improved progression-free survival according to a new study.

Beta-blockers related to better outcomes in ovarian cancer patients

Beta-blockers proved to be beneficial for ovarian cancer patients as they doubled survival, showed a clinical study of 1,425 patients.

Improved survival outcomes in ovarian cancer patients

Intraperitoneal chemotherapy proved to be beneficial for women with advanced ovarian cancer, a new study showed.

Chemo before surgery: a better option for ovarian cancer patients

Chemotherapy given before surgery to women with advanced ovarian cancer resulted in fewer side effects and a better quality of life, a new trial reveals.

Women with BRCA-positive breast cancer benefit from ovary removal

A review of 700 BRCA-positive breast cancer cases showed that removing ovaries significantly reduces the risk of death, especially for BRCA1 (62% lower).

A vaccine slows down advanced ovarian cancer

In a trial, a cancer vaccine has led to a significant drop in 3-year recurrence rate in advanced ovarian cancer patients, compared to treatment with surgery alone.

Immunotherapy holds promise for ovarian cancer patients

In a trial, immunotherapy kept the cancer away longer in patients with late-stage ovarian cancer, bringing personalized medicine one step closer to reality.

Addition to ovarian cancer standard treatment extends survival

Women receiving bevacizumab in addition to standard chemotherapy for ovarian cancer extended overall survival vs receiving standard chemotherapy treatment alone.

An algorithm can improve outcomes in ovarian cancer patients

Introducing the "Anderson Algorithm”, surgeons achieved complete removal of all visible tumors in ovarian cancer patients, resulting in improved survival rates.

Common menopause treatment increases ovarian cancer risk

Women who take hormone replacement therapy for menopause (even for a few years) may face an increased risk of ovarian cancer, according to a detailed analysis.

New drug approved in EU as treatment for ovarian cancer

Olaparib gained European approval for the treatment of advanced BCRA-mutated ovarian cancer. It is the first "PARP inhibitor" for this type of cancer.

FDA approves bevacizumab combined with chemotherapy for some ovarian cancers

The US FDA approved bevacizumab for treatment of patients with platinum resistant, recurrent epithelial ovarian, Fallopian tube, or primary peritoneal cancer.

Ovarian cancer risk could be lowered by tea and citrus products

Research has revealed that tea and citrus fruits and juices are associated with a reduced risk of ovarian cancer, after studying women aged 25-55 for 30 years.

Drug for BRCA mutated ovarian cancer one step closer to Europe

Olaparib, a drug for the maintenance treatment of platinum sensitive relapsed BRCA-mutated ovarian cancer has received positive opinion from European regulators.

New ovarian cancer test can help diagnosis and treatment selection

A new test may better diagnose ovarian cancer. The test will also help distinguish between benign and malignant tumors, and identify the type of malignant ones.

Lowering gynecologic cancer risk

There are several things women can do to lower their risk of developing certain types of cancer and improve their chances for survival if they do develop one of them, according to the Society of Gynecologic Oncology (SGO).

Biological therapy improves survival in women with recurrent ovarian cancer

Women with ovarian cancer that has recurred after chemotherapy have survived for longer after treatment with a biological therapy called cediranib, according to new results to be presented at the 2013 European Cancer Congress (ECC2013).

Targeted treatment plus chemotherapy could benefit women with ovarian cancer

Conventional chemotherapy could further extend life in some women with ovarian cancer when used in tandem with a new type of targeted treatment, a new international study shows.

Login to your account

Did you forget your password?